Translating Science. Transforming Lives. ACT DMD Clinical Trial Results
|
|
- Gillian Stone
- 6 years ago
- Views:
Transcription
1 Translating Science. Transforming Lives ACT DMD Clinical Trial Results
2 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of All statements, other than those of historical fact, contained in this presentation are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC; the timing of PTC s planned regulatory filings, including with the FDA, the EMA and other regulatory bodies outside of the United States and European Economic Area, or EEA; PTC s ability to maintain the marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation DMD in the EEA, which is conditioned upon, among other things, completion of ACT DMD and submission of the final report, including additional efficacy and safety data from ACT DMD, during 2015 and which is subject to annual review and renewal by the EMA following its reassessment of the risk benefit balance of the authorization; the clinical utility and potential advantages of Translarna; the rate and degree of market acceptance of Translarna; PTC s estimates regarding the potential market opportunity for Translarna, including the size of eligible patient populations and PTC s ability to identify such patients; the timing and scope of PTC s commercial and early access program launches; PTC s strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management. Other forward-looking statements may be identified by the words plan, guidance, anticipate, believe, estimate, expect, intend, may, predict, project, target, potential, will, would, could, should, continue, and similar expressions. PTC s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of final analyses of the data from ACT DMD, which may vary from PTC s initial analysis, lead to different (including more or less favorable) interpretations of the results than the analyses conducted to date, and identify further important information that is not available at the time of this presentation; whether the FDA or the EMA or other regulators agree with PTC s interpretation of the results of ACT DMD; expectations for regulatory approvals, including PTC s ability to make regulatory submissions in a timely manner (or at all), adverse decisions by regulatory authorities, other delay or deceleration of the regulatory process, and PTC s ability to meet existing or future regulatory standards with respect to Translarna; the scope of regulatory approvals or authorizations for Translarna (if any), including labeling and other matters that could affect the availability or commercial potential of Translarna; PTC s ability to commercialize and commercially manufacture Translarna in general and specifically as a treatment for nonsense mutation DMD, including its ability to successfully negotiate favorable pricing and reimbursement processes on a timely basis in the countries in which it may obtain regulatory approval, including the United States, EEA and other territories; the initiation, conduct and availability of data from clinical trials and studies; PTC s scientific approach and general development progress; the eligible patient base and commercial potential of Translarna and PTC s other product candidates; and the factors discussed in the Risk Factors section of PTC s most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC s other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that Translarna will receive full regulatory approval in any territory or maintain its current marketing authorization in the EEA, or prove to be commercially successful in general, or specifically with respect to the treatment of nonsense mutation Duchenne muscular dystrophy. The forward-looking statements contained herein represent PTC s views only as of the date of this presentation and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law. 2
3 Agenda ACT DMD clinical trial top-line data - Dr. Stuart Peltz Understanding clinical endpoints in Duchenne Muscular Dystrophy - Dr. Craig McDonald Review of ACT DMD & Study 007 clinical trial results - Dr. Stuart Peltz Translarna: A clinician s perspective - Dr. Craig Campbell Next steps for Translarna - Dr. Stuart Peltz 3
4 ACT DMD clinical trial top-line data 1. CEO Introduction Dr. Stuart Peltz 4
5 Phase 3 ACT DMD clinical trial confirms Translarna s benefit for nonsense mutation DMD patients In the overall Intent-to-Treat (ITT) population, Translarna demonstrated a 15m benefit in the six minute walk test (6MWT) which was not statistically significant (p=0.213, n=228) Translarna demonstrated a highly significant 47m benefit observed in 6MWT for the pre-specified 300m 400m baseline six minute walk distance (6MWD) patients (p=0.007, n=99) Pre-specified meta-analysis of combined ACT DMD and Study 007 show statistically significant 6MWT benefit of 22m (p=0.015, n=291) Key secondary endpoints favored Translarna including Time Function Tests (TFTs) across ACT DMD as well as the pre-specified meta-analysis North Star Ambulatory Assessment demonstrated benefit for Translarna No Translarna treated patients lost ambulation in the m baseline 6MWD group (0 / 47) vs four placebo patients in the same group (4 / 52) Translarna demonstrated a strong safety profile, consistent with previous studies Totality of data supports clinical benefit of Translarna 5 5
6 Understanding clinical endpoints in Duchenne muscular dystrophy Dr. Craig McDonald, U.C. Davis 1. CEO Introduction 6
7 Six minute walk test has been the most validated clinical endpoint utilized in ambulatory DMD trials Primary Endpoint 2008 ataluren 007 6MWD 2010 drisapersen 2013 tadalafil 2013 ACT DMD 2015 eteplirsen 2015 Antimyostatin Stair Climb Secondary Endpoints Time to 10% 6MWD Worsening 10-meter walk/run Stair climb Stair descend PedsQL Myometry North Star Ambulatory Assessment PODCI Note: ataluren study conducted by PTC Therapeutics; drisapersen study conducted by GSK / Prosensa (Biomarin); tadalafil study conducted by Lilly; eteplirsen study conducted by Sarepta; anti-myostatin mab study conducted by Pfizer. 7
8 6MWD inclusion criteria continue to evolve to select the population that can best demonstrate a treatment effect Study Inclusion Criteria for 6MWD 0 m 100 m 200 m 300 m 400 m 500 m 2008 ataluren 007: 75m 2010 drisapersen: 75m 2013 tadalafil: 200m 400m 2013 ataluren ACT DMD: >150m 80% Predicted* m Inclusion criteria Pre-specified Subgroup 2015 eteplirsen: 300m m 2015 anti-myostatin mab: Stair Climb: secs 8
9 Natural history data implies high performing DMD patients are stable / lower performing DMD patients decline rapidly Baseline 6M W D 350 (N = 34) Change in 6M W D, m ean (m ) G SK Ph 3 Placebo Baseline 6M W D <350 and >7 yr old (N = 23) -5 m -2 0 m ACT-DMD Placebo Baseline 6M W D 350 and 7 yr old (N = 70) 007 Baseline 6M W D <350 (N = 21) ACT-DMD Placebo -106 m Baseline 6M W D < m and 7 yr old (N = 39) -125 m -140 B a s e lin e Tim e (w eeks) 350m baseline 6MWT marks an inflection from moderate decline to more rapid declines over the following 48 weeks 9 9
10 Emerging MRI data reinforce the view that patients with baseline 6MWD <300m are at higher risk of losing ambulation 6MWD 300 Imaging data illustrate infiltration of muscle by fat and fibrous tissue Data courtesy of H. Lee Sweeney, Ph.D. Myology Institute, University of Florida 10
11 300m 400m baseline 6MWD may be the optimal window for conducting clinical trials in ambulatory DMD patients Six-minute walk test is the most validated clinical endpoint for ambulatory studies in Duchenne muscular dystrophy today Well validated across multiple natural history publications Decline in 6MWT is predictive of time to loss of ambulation; time to loss of upper arm movement and self feeding; time to required ventilation and ultimately mortality Significant patient to patient variability across disease state limits appropriate utilization window for clinical trials of 48 week duration 350m 6MWD predicts a transition from slow decline to a more rapid decline Higher performing boys in untreated arms tend to remain relatively stable (>70% predicted) Lower performing boys are at risk of losing ambulation regardless of treatment (<50% predicted) Important secondary outcome measures including Time Function Tests and North Star Ambulatory Assessment are becoming increasingly recognized as important endpoints to support 6MWT results 11
12 Detailed review of ACT DMD and Study 007 clinical trial results Dr. Stuart Peltz 12
13 ACT DMD study design and SAP developed in the context of Study 007 and evolving DMD understanding Phase 2b Study 007 enrolled a broad population 5 years and older; Minimum 6MWD of 75 meters Evolving DMD understanding indicate that high performing DMD boys are stable over 48 week while lower performing boys are at higher risk of losing ambulation ACT DMD study was designed to enrich for patients in the decline phase of the disease Inclusion / exclusion criteria designed to enrich a population with greatest opportunity to detect a clinical benefit over a 48 week study while being inclusive enough to enroll over a feasible time period (orphan disease) 7 years and older; Minimum 6MWD of 150 meters; maximum 6MWD of 80% predicted Statistical Analysis Plan focused on patients with highest potential to show clinical benefit Pre specified population with 300m 400m baseline 6MWD Meta analysis of ACT DMD and Study 007 providing greater statistical power to show Translarna s benefit 13
14 ACT DMD enrollment criteria were designed to enrich for the decline phase of Duchenne Age (years) Study 007 N=114 ACT DMD N=228 Mean (Range) 8.5 (5-20) 8.9 (7-14) 5-6 year olds (% / n) 20% / 23 N/A 7 9 year olds (% / n) 55% / 63 68% / years and older (% / n) 25% / 28 32% / 73 Baseline 6MWD (m) Mean 356m 364m < 300 m (% / n) 25% / 28 20% / m 400 m (% / n) 39% / 44 43% / 99 > 400 m (% / n) 37% / 42 37% / 84 Large subgroup of 99 patients in meter baseline 6MWD 14
15 ACT DMD results demonstrate consistent benefit for Duchenne patients MWD Treatment Difference vs. Placebo (m) m (p=0.026) 47m (p=0.007) 32m (p=0.020) 15m (p=0.213) citt 300m - 400m ITT 300m - 400m (n=114) (n=44) (n=228) (n=99) ** Study 007 ACT DMD ** pre-specified citt: corrected ITT ACT DMD study confirmed benefit for DMD patients previously observed in Study
16 Pre-specified 300m-400m baseline 6MWD patients showed benefit across primary and secondary endpoints 6MWD Treatment Difference vs. Placebo (m) m (p=0.007) Change in TFT Treatment vs. Placebo (s) s (p=0.066) 3.5s (p=0.030) 4.4s (p<0.001) MWT 10m Run / Walk Stair Climb Stair Descend ACT DMD 300m 400m Baseline 6MWD (n=99) Primary and secondary results consistent with Study 007 subgroup results 16
17 Pre-specified Meta-analysis shows statistically significant benefit across primary and secondary endpoints MWD Treatment Difference vs. Placebo (m) m (p=0.015*) Change in TFT Treatment vs. Placebo (s) s (p=0.025*) 1.6s (p=0.018*) 2.0s (p=0.004*) MWT 10m Walk Stair Climb Stair Descend Meta-analysis: ACT DMD and Study 007 (n=291) * Statistically significant 17
18 Pre-specified Meta-analysis in m baseline 6MWD patients shows more robust benefit across 6MWT and TFTs s (p<0.001) 6MWD Treatment Difference vs. Placebo (m) m (p<0.001) Change in TFT Treatment vs. Placebo (s) s (p=0.008) 3.4s (p<0.001) MWT 10m Walk Stair Climb Stair Descend Meta-analysis: ACT DMD and Study 007 (n=143) 18
19 Sensitivity analysis highlights Translarna s benefit in 6MWT demonstrated across multiple baseline 6MWD groups Baseline 6MWD, m 0 m 100 m 200 m 300 m 400 m 500 m P Pre-Specified 300 to < m Sensitivity 250 to < Sensitivity 200 to < Sensitivity 300 to <
20 Loss of ambulation occurred more frequently in placebo patients with m baseline 6MWD across both ACT DMD and Study 007 Percentage of Patients Losing Ambulation (%) -1% -3% -5% -7% -9% -11% -13% 9% (2 of 22) 0% (0 of 22) 8% (4 of 52) 0% (0 of 47) -15% Placebo Translarna Placebo Translarna Study m-400m Baseline 6MWD ACT DMD 300m-400m Baseline 6MWD Six placebo patients with 300m-400m baseline 6MWD lost ambulation vs. no Translarna patients across both ACT DMD and Study
21 North Star Ambulatory Assessment favored Translarna with benefit in m baseline 6MWD patients Linear North Star Ambulatory Assessment Score Linear NSAA Score ITT p = ITT (N=228) 300m Subgroup 400m (N=99)* baseline p = Mean and 95% CI, (score) NSAA Score favored Translarna by 1.5 points in the ITT population and 4.3 points in the 300m 400m baseline population 21
22 Totality of data shows clinical benefit across primary and secondary endpoints Decline Improvement Meters, mean and 95% CI MWD Meta-Analysis (N=291) ACT DMD (N=228) Phase 2 Subgroup (N=63)* 10-m walk/run 4-stair climb 4-stair descend * Including only patients in the ambulatory decline phase subgroup matching ACT DMD entry criteria Seconds, mean and 95% CI 22
23 Translarna: A clinician s perspective Dr. Craig Campbell, London Health Science Center 23
24 Translarna: A clinician s perspectives Benefit risk profile is critical in the decision to prescribe for DMD boys Current standard of care includes steroids which while beneficial, are associated with complications Translarna has an important clinical benefit without increasing the patient burden Encouraged to see a benefit demonstrated over a one year period in the prespecified endpoints Cumulative benefit will be seen over time but clinicians will recognize the benefit seen over a one year study Both the 47m benefit demonstrated in the pre-specified 300m-400m combined with 15m across the broader population is important and indicative of longer term benefit for patients Totality of the data as demonstrated in the meta-analysis provides compelling evidence of clinical benefit for DMD patients New data from the Phase 3 trial is a key piece of additional information supporting Translarna s effectiveness 24
25 Next Steps for Translarna Dr. Stuart Peltz 25
26 Next Steps for Translarna Plan to complete rolling NDA for Translarna in nmdmd and submit to the FDA before year-end 2015 Submit results of ACT DMD to EMA Complete enrollment of ACT CF Phase 3 clinical trial Prepare for EMA review and discussion of Translarna CF submission Continue to explore the potential for Translarna in additional nonsense mutation-based genetic disorders PTC plans to finalize rolling NDA for Translarna in nmdmd and complete submission to FDA by year-end
27 Q&A Stuart Peltz, CEO Dr. Craig Campbell, London Health Science Center Dr. Craig McDonald, U.C. Davis 27
Catabasis Pharmaceuticals Q May 2018
Catabasis Pharmaceuticals Q1 2018 May 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationSummary 1. Comparative effectiveness of ataluren Study 007
Cost-effectiveness of Ataluren (Transarna TM ) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophy gene in ambulatory patients aged 5 years and older The
More informationEdasalonexent (CAT-1004) Program
Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy Joanne M. Donovan, MD, PhD Chief Medical Officer, Catabasis Pharmaceuticals
More informationBringing Differentiated Therapies to Duchenne Patients Stuart Peltz, PhD
Bringing Differentiated Therapies to Duchenne Patients Stuart Peltz, PhD Jul-18 1 Main Objectives Translarna TM (ataluren) Update FDA pathway forward for NDA Ongoing clinical trials EMFLAZA (deflazacort)
More informationEdasalonexent (CAT-1004)
Edasalonexent (CAT-1004) An NF-κB Inhibitor in Development for Patients with Duchenne Muscular Dystrophy Joanne M. Donovan, MD PhD Chief Medical Officer 17 February 2018 1 Forward Looking Statements This
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationGSK Q&A For Patient Advocacy Groups: 04 October 2013 For reactive use in response to enquiries from patient groups only
1. Will assessments and visits continue now that the patients are no longer receiving study treatment? Yes, while dosing of boys in the ongoing studies (DMD114349, DMD115501 and DMD114673) has been placed
More informationAccessing EMFLAZA (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference June 29, 2017; 4:00pm Stuart Peltz, PhD PTC
Accessing EMFLAZA (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference June 29, 2017; 4:00pm Stuart Peltz, PhD PTC Therapeutics, South Plainfield, NJ Forward looking statements within
More informationSoutheast Regional Office 2870 Peachtree Road, PMB 196 Atlanta, Georgia 30305
800-532-7667 856-488-4500 FAX: 856-661-9797 EMAIL: msaa@msassociation.org College of Pharmacy Oregon State University Attn: Oregon Pharmacy and Therapeutics Committee Corvallis, OR 97331 November 27th,
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationCAP-1002: Cardiosphere-Derived Cells PPMD s 2018 End Duchenne Tour St. Paul, MN. 1 Capricor, Inc. PPMD s 2018 End Duchenne Tour April 2018
CAP-1002: Cardiosphere-Derived Cells PPMD s 2018 End Duchenne Tour St. Paul, MN NASDAQ: CAPR 1 Capricor, Inc. PPMD s 2018 End Duchenne Tour April 2018 April 2018 Forward-Looking Statements Statements in
More informationRoche/Genentech Anti-Myostatin Adnectin RG6206 Development Program in Duchenne
Roche/Genentech Anti-Myostatin Adnectin RG6206 Development Program in Duchenne Michelle Krishnan MD, PhD. Translational Medicine Leader, Roche information is presented only for purposes of providing a
More informationAdvancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationMoveDMD SM : A Phase 1/2 Clinical Trial with CAT-1004 in Boys with Duchenne Muscular Dystrophy
MoveDMD SM : A Phase 1/2 Clinical Trial with CAT-1004 in Boys with Duchenne Muscular Dystrophy EL Finanger 1 JM Donovan 2, K Vandenborne 3, HL Sweeney 3, G Tennekoon 4, SW Yum 4, MC Mancini 2, JR Danis
More informationBroad and clinically important benefits beyond the initial registrational endpoints are now reported.
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationESC 2018 Tafamidis Analyst Briefing. August 27, 2018
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationIdebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals,
Idebenone (Raxone ) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Kristina Nygren, MD CMO, Head of Development Santhera Pharmaceuticals, Inc Disclaimer This presentation is not and under no circumstances
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More informationExondys 51 (eteplirsen) injection Policy Number: Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019
Exondys 51 (eteplirsen) injection Policy Number: 5.01.618 Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationInformation provided to Duchenne muscular dystrophy patient organisations regarding Raxone
Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) April 26 th 2018 Raxone tablets
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationKeyzilen TM Program Update
Keyzilen TM Program Update October 11, 2016 Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial risks and uncertainties.
More informationNew Drug Evaluation: Eteplirsen injection, intravenous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPTC Therapeutics, Inc. June 2014
PTC Therapeutics, Inc. June 2014 Forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements,
More informationESTABLISH 2 Top Line Data Release
The Future of Anti-Infectives ESTABLISH 2 Top Line Data Release March 25, 2013 1 Forward Looking Statements Statements contained in this data release regarding matters that are not historical facts are
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationSWISS BIOTECH DAY 2018
SWISS BIOTECH DAY 2018 Basel, 3 May 2018 Thomas Meier, CEO Disclaimer This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
More informationDEFLAZACORT Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668
Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of Duchenne muscular dystrophy
More informationClinical Policy: Eteplirsen Reference Number: NH.PHAR.288 Effective Date: 12/16
Clinical Policy: Reference Number: NH.PHAR.288 Effective Date: 12/16 Last Review Date: 12/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More information(direct) (609) (mobile)
MEDIA Sanofi-aventis Bristol-Myers Squibb Ingrid Görg-Armbrecht Laura Hortas + 33 153-774-625 (direct) (609) 252-4587 +33 686-056-688 (mobile) laura.hortas@bms.com ingrid.goerg-armbrecht@sanofi-aventis.com
More informationXARACOLL Phase 3 Results Webcast. MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016
XARACOLL Phase 3 Results Webcast MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016 Forward Looking Statements This presentation contains forward-looking statements about our ongoing development of XARACOLL
More informationNeoCart Phase 3 Clinical Trial Results Call
NeoCart Phase 3 Clinical Trial Results Call September 5, 2018 Disclaimer Regarding Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements.
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.PHAR.288 Effective Date: 12.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationPimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs
Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements.
More informationResults Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that
More informationOppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer
Oppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer New York City 20th March 2019 1 Safe Harbor Forward-looking statements Statements contained in this presentation about
More informationSubject: Eteplirsen (Exondys 51)
09-J2000-69 Original Effective Date: 10/15/16 Reviewed: 12/12/18 Revised: 01/01/19 Next Review: 12/11/18 Subject: Eteplirsen (Exondys 51) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationAdvancing Innovative Therapies for Neurological Diseases
Advancing Innovative Therapies for Neurological Diseases Phase 3 Topline Rimegepant 75 mg Zydis ODT December 03, 2018 NYSE: BHVN 2018 Biohaven Pharmaceuticals. All rights reserved. Disclaimer This presentation
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationHow to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy
How to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy CTs in rare diseases London 30 th November 2015 Michela Guglieri JWMDRC Newcastle upon Tyne Michela.guglieri@Newcastle.ac.uk
More informationHow is the introduction of a new medicine regulated in the UK?
Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) A medicine called Raxone, which
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationPhase 3c Topline Results. Page 1
Phase 3c Topline Results Page 1 Important Information Any statements in this presentation about future expectations, plans and prospects for the Company including the development and regulatory status
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationA Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism. Enclomiphene (fka Androxal )
A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism Enclomiphene (fka Androxal ) Repros Disclaimer Any statements made by the Company that are not historical facts contained
More informationPPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D
PPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D Disclosure and Disclaimer Dr. Bettica is a full time employee of Italfarmaco, the manufacturer of Givinostat Givinostat (ITF2357) is currently
More informationClinical Commissioning Policy: Ataluren for the treatment of nmdmd
Clinical Commissioning Policy: Ataluren for the treatment of nmdmd Reference: NHS ENGLAND XXX/X/X 1 England NHS England Clinical Commissioning Policy: Ataluren for the treatment of nmdmd Prepared by NHS
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationSoliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018
Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationREPROS THERAPEUTICS. Dedicated to Treating Male and Female Reproductive Disorders. Corporate Presentation. August 2017
REPROS THERAPEUTICS Dedicated to Treating Male and Female Reproductive Disorders Corporate Presentation August 2017 Safe Harbor Any statements made by the Company that are not historical facts contained
More informationBMS : An Anti-Myostatin Adnectin Targeting Duchenne Muscular Dystrophy
BMS-986089: An Anti-Myostatin Adnectin Targeting Duchenne Muscular Dystrophy Leslie Jacobsen, MD Medical Lead GS Tirucherai, M Ahlijanian, F Luo, C Bechtold and the BMS Anti-Myostatin Team PPMD Connect
More informationForward-looking statements
PTC Therapeutics, Inc. May 2014 Forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements,
More informationGene Therapy With a Difference By ANDREW POLLACK
September 23, 2013 Gene Therapy With a Difference By ANDREW POLLACK Terri Ellsworth is convinced that her 12-year-old son Billy, who has Duchenne muscular dystrophy, is being helped by an experimental
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More information58. Translarna drug Policy for use. The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care:
58. Translarna drug Policy for use The Hon. Member for Douglas South (Mrs Beecroft) to ask the Minister for Health and Social Care: What his policy is regarding the use of the drug Translarna? The President:
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationRoclatan TM Mercury 2 Phase 3 Topline Results
Roclatan TM Mercury 2 Phase 3 Topline Results 1 Important Information Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationArea Drug and Therapeutics Committee Prescribing
Area Drug and Therapeutics Committee Prescribing Supplement No 103 In this issue Drugs reviewed by the SMC in March 2016 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial -- Statistically significantly more patients treated with
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.CPA.188 Effective Date: 02.15.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages.
Cost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages. The NCPE has issued a recommendation regarding the cost-effectiveness of elosulfase alfa
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May
BRAND NAME Emflaza GENERIC NAME Deflazacort MANUFACTURER Marathon Pharmaceuticals, LLC DATE OF APPROVAL February 9, 2017 PRODUCT LAUNCH DATE Anticipated availability in early 2017 REVIEW TYPE Review type
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More informationMessage from Founder. December Special. End of Year Giving. Research
December 2014 Special Message from the Founder Message from Founder End of Year Giving to Sponsor Duplication for with Dr. Kevin Flanigan from Nationwide Children s Hospital BioMarin and Prosensa Holding
More information4th International Summer School on Rare Disease and Orphan Drug Registries. The Italian Duchenne and Becker Muscular Dystrophy Patients Registry
4th International Summer School on Rare Disease and Orphan Drug Registries The Italian Duchenne and Becker Muscular Dystrophy Patients Registry Fernanda De Angelis Parent Project Onlus Organised by Istituto
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationConference Call for Investment Community. Nov 19, 2018
Conference Call for Investment Community Nov 19, 2018 Agenda for Today s Call Topic Safe Harbor Statement Opening Remarks AR101 for Peanut Allergy Speaker Laura Hansen, PhD, VP, Investor Relations Jayson
More informationAerie Pharmaceuticals, Inc. Additional Rhopressa Rocket 1 Analyses and Path Forward
Aerie Pharmaceuticals, Inc. Additional Rhopressa Rocket 1 Analyses and Path Forward May 7, 2015 1 Important Information Any discussion of the potential use or expected success of our product candidates
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More information